Burning Rock Biotech Limited (BNR | DoD: -1.78% | YTD: +12.31% | SmallCap: 3M)

• Profile: Develops and sells cancer therapy selection tests
• Reporting: Burning Rock Reports Second Quarter 2025 Financial Results (Full Text)

Sintx Technologies, Inc. (SINT | DoD: +25.80% | YTD: +50.96% | SmallCap: 7M)

• Profile: A leader in advanced ceramics for medical applications
• Financing: SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds (Full Text)

Solventum Corporation (SOLV | DoD: +0.47% | YTD: +10.30% | MidCap: 12.8B)

• Profile: A healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs
• Financing: Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers (Full Text)

DENTSPLY SIRONA Inc. (XRAY | DoD: +2.02% | YTD: -20.40% | MidCap: 3.2B)

• Profile: An American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries
• Acquisition: Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives (Full Text)

Butterfly Network, Inc. (BFLY | DoD: +1.96% | YTD: -60.71% | SmallCap: 580M)

• Profile: A digital health company transforming care with handheld, whole-body ultrasound and intuitive software
• Clinical: Rutgers Robert Wood Johnson Medical School Study Published in JAMA Confirms Butterfly-Enabled POCUS Program Heavily Focused on LUNG US with AI Assistance Reduces Stay and Cost (Full Text)

Femasys Inc. (FEMY | DoD: +2.09% | YTD: -65.83% | SmallCap: 22M)

• Profile: A leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products
• Regulatory: Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand (Full Text)

IceCure Medical Ltd (ICCM | DoD: -2.83% | YTD: -16.26% | SmallCap: 59M)

• Profile: Developer of a liquid nitrogen-based system for freezing and destroying benign and cancerous tumors in the breast, kidney, lung and other areas
• Clinical: Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate (Full Text)

Johnson & Johnson (JNJ | DoD: -0.18% | YTD: +26.87% | LargeCap: 373.9B)

• Profile: Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide
• Clinical: Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer (Full Text)

Johnson & Johnson (JNJ | DoD: -0.18% | YTD: +26.87% | LargeCap: 373.9B)

• Profile: Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide
• Clinical: RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer (Full Text)

Lifeward Ltd. (LFWD | DoD: -4.76% | YTD: -76.21% | SmallCap: 13M)

• Profile: Maker of industry-leading personal exoskeleton for persons with spinal cord injury
• Regulatory: Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton (Full Text)

Microbot Medical Inc. (MBOT | DoD: +8.61% | YTD: +221.05% | SmallCap: 97M)

• Profile: A company that develops and commercializes robotic technologies for endovascular procedures
• FDA Clearance: Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System (Full Text)

Pulse Biosciences, Inc. (PLSE | DoD: -0.40% | YTD: -15.06% | MidCap: 1.1B)

• Profile: Operates as a novel bioelectric medicine company
• FDA Clearance: Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation (Full Text)

Ainos, Inc. (AIMD | DoD: -3.86% | YTD: +39.60% | SmallCap: 14M)

• Profile: A healthcare company, focuses on the development of novel point-of-care testing therapeutics based on very low-dose interferon alpha and synthetic RNA-driven preventative medicine
• Product: Ainos to Showcase AI Nose at SEMICON Taiwan 2025 (Full Text)

Alcon Inc. (ALC | DoD: +1.60% | YTD: -3.22% | LargeCap: 42.1B)

• Profile: The global leader in eye care dedicated to helping people see brilliantly
• Product: Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025 (Full Text)

Alcon Inc. (ALC | DoD: +1.60% | YTD: -3.22% | LargeCap: 42.1B)

• Profile: The global leader in eye care dedicated to helping people see brilliantly
• Product: Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025 (Full Text)

Bausch + Lomb Corporation (BLCO | DoD: +2.88% | YTD: -16.61% | MidCap: 4.1B)

• Profile: A leading global eye health company dedicated to helping people see better to live better
• Product: Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States (Full Text)

Guardant Health, Inc. (GH | DoD: -2.00% | YTD: +89.27% | MidCap: 5.7B)

• Profile: A leading precision oncology company
• Partnership: Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States (Full Text)

Quantum-Si incorporated (QSI | DoD: +0.93% | YTD: -74.65% | SmallCap: 324M)

• Profile: A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS)
• Product: Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing (Full Text)

Sintx Technologies, Inc. (SINT | DoD: +25.80% | YTD: +50.96% | SmallCap: 7M)

• Profile: A leader in advanced ceramics for medical applications
• Patent: SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent (Full Text)

Cytosorbents Corporation (CTSO | DoD: -1.01% | YTD: +4.96% | SmallCap: 54M)

• Profile: A leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification
• Event: CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day (Full Text)

DIH Holding US, Inc. (DHAI | DoD: +4.62% | YTD: -82.88% | SmallCap: 11M)

• Profile: Operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry
• Announcement: DIH Holding US, Inc. Receives Nasdaq Staff Determination Letter (Full Text)

Delcath Systems, Inc. (DCTH | DoD: +4.95% | YTD: -7.61% | SmallCap: 552M)

• Profile: An interventional oncology company focused on the treatment of primary and metastatic liver cancers
• Announcement: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Full Text)

Lucid Diagnostics Inc. (LUCD | DoD: -0.72% | YTD: +72.54% | SmallCap: 126M)

• Profile: A commercial-stage, cancer prevention medical diagnostics company
• Event: Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 (Full Text)

Nyxoah SA (NYXH | DoD: +4.04% | YTD: -34.40% | SmallCap: 291M)

• Profile: A medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA)
• Report: Publication relating to transparency notifications (Full Text)

Star Equity Holdings, Inc. (STRR | DoD: -4.41% | YTD: -26.76% | SmallCap: 8M)

• Profile: Engages in the construction business
• Announcement: Star Equity Holdings, Inc. RPO Subsidiary Rebrands to Hudson Talent Solutions (Full Text)

Adagio Medical Holdings, Inc. (ADGM | DoD: -4.24% | YTD: +35.04% | SmallCap: 18M)

• Profile: A developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias
• Leadership Update: Adagio Medical Expands Chief Business Officer Deborah Kaster's Role to Include Chief Financial Officer Responsibilities (Full Text)